Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement，make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement．


## 透雲生物 <br> Ty Biotech

# Touyun Biotech Group Limited透雲生物科技集團有限公司 <br> （Incorporated in Bermuda with limited liability） 

（Stock Code：1332）

## SUPPLEMENTAL ANNOUNCEMENT

## DATE OF BOARD MEETING

Reference is made to the announcement of Touyun Biotech Group Limited（the ＂Company＂）dated 21 March 2022 （the＂Announcement＂）in relation to the notice of board meeting of the Company．Unless otherwise defined herein，capitalized terms used in the announcement shall have the same meaning as those defined in the Announcement．

The Board would like to provide supplemental information in respect of the explanation on the delay of the publication of the annual results announcement which shall be agreed with the Company＇s auditors by 31 March 2022 in accordance with Rule 13.49 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited：

The progress of the relevant audit field works in the People＇s Republic of China（the ＂PRC＂）has been disrupted in light of the quarantine measures and travel restrictions imposed in the PRC and Hong Kong due to the outbreak of the coronavirus disease （COVID－19）．

Save as disclosed above，all other information in the Announcement shall remain unchanged．
By order of the Board
Touyun Biotech Group Limited Wang Liang
Chairman
Hong Kong， 23 March 2022

As at the date of this announcement, the Board comprised the following directors:

Executive Directors
Mr. Wang Liang (Chairman)
Mr. Du Dong

Non-executive Directors
Mr. Chen Hui
Ms. Tian Yuze
Mr. Jia Wenjie
Mr. Zhang Lele
Independent Non-executive Directors
Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen
Mr. Hu Guohua

